Our transcriptomic and immunoblotting data indicated that mTOR- and MAPK-associated pathways, including the ERK1/2, AKT, AMPK and mTOR pathways, respond to the NR modulators in the early stage of treatment and are associated with the inhibition of osteosarcoma growth. The gene discussed is AKT1; the disease is osteosarcoma.